Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

NCT03739710 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

175

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: Docetaxel
DRUG: Feladilimab
DRUG: Ipilimumab
DRUG: GSK4428859A
DRUG: Dostarlimab
DRUG: GSK6097608

Sponsor

GlaxoSmithKline

Collaborators

[object Object]